Beckman Coulter Diagnostics will unveil its new DxC 500 AU Chemistry Analyzer at Medlab Middle East (Dubai, February 5 – 8, 2024). The DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories.
The DxC 500 AU Chemistry Analyzer, which is only for in vitro diagnostic use, features advanced automation technology, onboard guided workflows, and standardized reagents for use across healthcare networks. Its menu of more than 120 assays has been independently and objectively verified for high quality Six Sigma performance, supporting confidence in clinical results, reducing QC trouble shooting and lab operational costs.
The DxC 500 AU Chemistry Analyzer is available throughout North America and the Middle East. Global commercial availability is planned for March 2024.
The new DxC 500 AU Chemistry Analyzer advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter’s AU clinical chemistry systems, positively impacting clinical decision-making and patient outcomes,” said Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics.
To view the source version, please click HERE.